➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Johnson and Johnson
AstraZeneca
Dow
Colorcon

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NETUPITANT; PALONOSETRON HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Netupitant; Palonosetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01339260 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 2011-04-01 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01339260 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2011-04-01 NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.
NCT01376297 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Parexel Phase 3 2011-07-01 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT01376297 A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2011-07-01 NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone. The objective of the study is to evaluate if netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed PSI CRO AG Phase 3 2015-11-01 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT02517021 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed Helsinn Healthcare SA Phase 3 2015-11-01 NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
NCT03008213 Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV Terminated University of California, San Diego Phase 2 2017-01-01 Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant impact on a patient's quality of life. The chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Nausea and vomiting that occurs within the first day of the administration of chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the treatment of refractory CINV
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Netupitant; Palonosetron Hydrochloride

Condition Name

Condition Name for Netupitant; Palonosetron Hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 8
Hematopoietic Cell Transplantation Recipient 1
Chemotherapy-induced Nausea and Vomiting (CINV) 1
Nausea and Vomiting, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Netupitant; Palonosetron Hydrochloride
Intervention Trials
Vomiting 12
Nausea 10
Neoplasms 2
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Netupitant; Palonosetron Hydrochloride

Trials by Country

Trials by Country for Netupitant; Palonosetron Hydrochloride
Location Trials
United States 55
Italy 7
Ukraine 4
Russian Federation 3
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Netupitant; Palonosetron Hydrochloride
Location Trials
Ohio 4
California 4
Florida 4
Texas 3
South Carolina 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Netupitant; Palonosetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Netupitant; Palonosetron Hydrochloride
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 2
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Netupitant; Palonosetron Hydrochloride
Clinical Trial Phase Trials
Recruiting 5
Completed 4
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Netupitant; Palonosetron Hydrochloride

Sponsor Name

Sponsor Name for Netupitant; Palonosetron Hydrochloride
Sponsor Trials
Helsinn Healthcare SA 7
Consorzio Oncotech 2
PSI CRO AG 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Netupitant; Palonosetron Hydrochloride
Sponsor Trials
Other 10
Industry 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Mallinckrodt
Medtronic
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.